AGAnastas Gospodinov

Anastas Gospodinov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anastas Gospodinov has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular Genetic Characterization of Commercial Probiotics Saccharomyces boulardii (Enterol®, Biocodex) and Baker’s (Cosm-O-tentic®, Puratos) Yeasts

    by Nadezhda Zhuchkina, Alexandra Kokoreva, Darya Kopylova, Rossitsa Hristova, Anastas Gospodinov, Svetla Danova, Natalia Koltovaya

    Saccharomyces boulardii is widely distributed throughout the world. Storage in various laboratories leads to the accumulation of independent genetic changes. To introduce the S. boulardii strain into scientific use, and, particularly, in space biology, it must be thoroughly characterized. Since it lacks genetic markers, simple methods for identifying the probiotic strain and distinguishing it from laboratory strains of Saccharomyces cerevisiae must be developed. In addition, it is necessary to select appropriate genetic systems for monitoring genetic stability. We have characterized three strains as potential space flight objects, derived from preparations—the well-known Enterol® (Biocodex), based on S. boulardii strain CNCM I-745, and Cosm-O-tentic® (Puratos). The combined characteristics are consistent with S. cerevisiae; the species assignments of the Puratos isolates remain provisional because their D1/D2 comparisons were not taxonomically conclusive. However, isolates show differences in nucleotide sequences, ploidy, structure of MAL and CUP1 loci, and antifungal susceptibility. Copper sensitivity and fungicide susceptibility are candidate markers for future genetic-stability studies; their reliability during serial passage or storage and the genetic basis of any phenotypic changes require validation.

  • SARS-CoV-2 NSP8 derived peptide effectively suppresses the activity of helicase NSP13

    by Shina Pashova, Peicho Petkov, Rositsa Hristova, Elena Krachmarova, Genoveva Nacheva, Anastas Gospodinov, Elena Lilkova, Nevena Ilieva, Miroslav Rangelov, Nadezhda Todorova, et al.

    Highlights: • NSP8-N binds NSP13, occupying residues required for TBK1 and NSP8-NSP13 association. • NSP8-N blocks NSP13-TBK1, occupies RTC, and inhibits immune evasion and replication. • NSP8-N restores the IFN-β expression in cells coexpressing NSP13.


  • Open Access

    Srcap Chromatin Remodeler Is Required for Efficient Replication Dynamics in Mammalian Cells

    by Stefka K. Dzhokova, Rossitsa H. Hristova, Peter S. Botev, Temenouga N. Guecheva, Anastas G. Gospodinov

    The SNF2-related chromatin remodeler Srcap is the principal ATPase responsible for the deposition of the histone variant H2A.Z at promoters and regulatory chromatin regions. Although this activity is known to modulate transcription, its contribution to DNA replication remains unexplored. Here we show that Srcap is required for efficient replication fork progression and origin firing in mammalian cells. Using RNA interference in human PC3 cells, we found that Srcap depletion leads to a ~25% reduction in fork elongation rate, decreased replication fork density, accumulation of the replication-stress marker γH2AX, and reduced chromatin-bound H2A.Z. High-resolution expansion microscopy further revealed diminished intensity and increased spacing of replication foci, consistent with reduced origin activation. Transcriptomic analysis of published data identified broad downregulation of replication-associated genes. These data uncover a dual mechanism by which Srcap sustains replication efficiency—through both H2A.Z-dependent chromatin organization and transcriptional maintenance of the replication machinery. Our findings establish Srcap as an important coordinator of replication dynamics, with implications for genome stability.


  • Open Access

    Metformin Inhibits Cell Motility and Proliferation of Triple-Negative Breast Cancer Cells by Blocking HMGB1/RAGE Signaling

    by Shazie Yusein-Myashkova, Desislava Vladimirova, Anastas Gospodinov, Iva Ugrinova, Jordana Todorova

    High-mobility group box 1 (HMGB1) is a nuclear chromatin protein overexpressed in various cancers and linked to tumor progression. Outside the cell, HMGB1 binds to receptors such as the receptor for advanced glycation end products (RAGE), promoting metastasis. Targeting this signaling pathway may provide a new therapeutic strategy for aggressive cancers. Metformin, a well-established antidiabetic drug, directly interacts with HMGB1, inhibiting its pro-inflammatory functions. This study investigates metformin’s effects on the HMGB1/RAGE signaling pathway in triple-negative breast cancer (TNBC) cells. Using wound-healing and colony formation assays, we demonstrate that metformin reduces HMGB1-induced cell migration and proliferation. Immunoblotting and immunofluorescence analyses reveal that metformin decreases RAGE stabilization on the cell membrane, disrupts NF-κB signaling, and reverses the epithelial-to-mesenchymal transition (EMT) by increasing E-cadherin, reducing vimentin, and stabilizing β-catenin at the cell membrane. Furthermore, metformin lowers HMGB1 and RAGE protein levels, disrupting the positive feedback loop that promotes cancer aggressiveness. These findings highlight metformin’s potential as a therapeutic agent in TNBC by inhibiting HMGB1/RAGE-driven metastasis.


  • Open Access

    Interferon-γ as a Potential Inhibitor of SARS-CoV-2 ORF6 Accessory Protein

    by Elena Krachmarova, Peicho Petkov, Elena Lilkova, Dayana Stoynova, Kristina Malinova, Rossitsa Hristova, Anastas Gospodinov, Nevena Ilieva, Genoveva Nacheva, Leandar Litov

    The ORF6 protein of the SARS-CoV-2 virus plays a crucial role in blocking the innate immune response of the infected cells by inhibiting interferon pathways. Additionally, it binds to and immobilises the RAE1 protein on the cytoplasmic membranes, thereby blocking mRNA transport from the nucleus to the cytoplasm. In all these cases, the host cell proteins are tethered by the flexible C-terminus of ORF6. A possible strategy to inhibit the biological activity of ORF6 is to bind its C-terminus with suitable ligands. Our in silico experiments suggest that hIFNγ binds the ORF6 protein with high affinity, thus impairing its interactions with RAE1 and, consequently, its activity in viral invasion. The in vitro studies reported here reveal a shift of the localisation of RAE1 in ORF6 overexpressing cells upon treatment with hIFNγ from predominantly cytoplasmic to mainly nuclear, resulting in the restoration of the export of mRNA from the nucleus. We also explored the expression of GFP in transfected-with-ORF6 cells by means of fluorescence microscopy and qRT-PCR, finding that treatment with hIFNγ unblocks the mRNA trafficking and reinstates the GFP expression level. The ability of the cytokine to block ORF6 is also reflected in minimising its negative effects on DNA replication by reducing accumulated RNA-DNA hybrids. Our results, therefore, suggest hIFNγ as a promising inhibitor of the most toxic SARS-CoV-2 protein.


  • Open Access

    Interferon- γ as a Potential Inhibitor of SARS-CoV-2 ORF6 Accessory Protein

    by Elena Krachmarova, Peicho Petkov, Elena Lilkova, Dayana Stoynova, Kristina Malinova, Rossitsa Hristova, Anastas Gospodinov, Nevena Ilieva, Genoveva Nacheva, Leandar Litov

    ORF6 protein of the SARS-CoV-2 virus plays a crucial role in blocking the innate immune response of the infected cells by inhibiting interferon pathways. Additionally, it binds and immobilises the RAE1 protein onto the cytoplasmic membranes, thereby blocking the transport of mRNA from the nucleus to the cytoplasm. In all these cases the host cell proteins are tethered by the flexible C-terminus of ORF6. A possible strategy to inhibit the biological activity of ORF6 is to bind its C-terminus with suitable ligands. Our in silico experiments suggest that hIFN γ binds the ORF6 protein with high affinity, thus impairing its interactions with RAE1 and, consequently, its activity in viral invasion. The here reported in vitro studies reveal a shift of the localization of RAE1 in ORF6 overexpressing cells upon treatment with hIFN γ from predominantly cytoplasmic to mainly nuclear, resulting in restoration of the export of mRNA from the nucleus. We also explored the expression of GFP in transfected with ORF6 cells by means of fluorescence microscopy and qRT-PCR, finding that treatment with hIFN γ unblocks the mRNA trafficking and reinstates the GFP expression level. The ability of the cytokine to block ORF6 is also reflected in minimising its negative effects on DNA replication by reducing accumulated RNA-DNA hybrids. Our results, therefore, suggest hIFN γ as a promising inhibitor of the most toxic SARS-CoV-2 protein.

  • Open Access

    Insights into the SARS-CoV-2 ORF6 Mechanism of Action

    by Elena Krachmarova, Peicho Petkov, Elena Lilkova, Nevena Ilieva, Miroslav Rangelov, Nadezhda Todorova, Kristina Malinova, Rossitsa Hristova, Genoveva Nacheva, Anastas Gospodinov, et al.

    ORF6 is responsible for suppressing the immune response of cells infected by the SARS-CoV-2 virus. It is also the most toxic protein of SARS-CoV-2, and its actions are associated with the viral pathogenicity. Here, we study in silico and in vitro the structure of the protein, its interaction with RAE1 and the mechanism of action behind its high toxicity. We show both computationally and experimentally that SARS-CoV-2 ORF6, embedded in the cytoplasmic membranes, binds to RAE1 and sequesters it in the cytoplasm, thus depleting its availability in the nucleus and impairing nucleocytoplasmic mRNA transport. This negatively affects the cellular genome stability by compromising the cell cycle progression into the S-phase and by promoting the accumulation of RNA–DNA hybrids. Understanding the multiple ways in which ORF6 affects DNA replication may also have important implications for elucidating the pathogenicity of SARS-CoV-2 and developing therapeutic strategies to mitigate its deleterious effects on host cells.


  • Open Access

    Insights into the SARS-CoV-2 ORF6 Mechanism of Action

    by Elena Krachmarova, Peicho Petkov, Elena Lilkova, Nevena Ilieva, Miroslav Rangelov, Nadezhda Todorova, Kristina Malinova, Rossitsa Hristova, Genoveva Nacheva, Anastas Gospodinov, et al.

    ORF6 is responsible for suppressing the immune response of cells infected by the SARS-CoV-2 virus. It is also the most toxic protein of SARS-CoV-2, and its actions are associated with the viral pathogenicity. Here we study in silico and in vitro the structure of the protein, its interaction with RAE1, and the mechanism of action behind its high toxicity. We show both computationally and experimentally that SARS-CoV-2 ORF6, embedded in the membranes of the endoplasmic reticulum, binds to RAE1 and sequesters it in the cytoplasm, thus depleting its availability in the nucleus and impairing nucleocytoplasmic mRNA transport. This negatively affects the cellular genome stability by compromising the cell cycle progression into the S-phase and by promoting the accumulation of RNA-DNA hybrids. Understanding the multiple ways in which ORF6 affects DNA replication may also have important implications for elucidating the pathogenesis of SARS-CoV-2 and developing therapeutic strategies to mitigate its deleterious effects on host cells.


  • Chromatin regulators in DNA replication and genome stability maintenance during S-phase

    by Anastas Gospodinov, Stefka Dzhokova, Maria Petrova, Iva Ugrinova

  • Open Access

    Molecular Mechanism of the Anti-Inflammatory Action of Heparin

    by Leandar Litov, Peicho Petkov, Miroslav Rangelov, Nevena Ilieva, Elena Lilkova, Nadezhda Todorova, Elena Krachmarova, Kristina Malinova, Anastas Gospodinov, Rossitsa Hristova, et al.

    Our objective is to reveal the molecular mechanism of the anti-inflammatory action of low-molecular-weight heparin (LMWH) based on its influence on the activity of two key cytokines, IFNγ and IL-6. The mechanism of heparin binding to IFNγ and IL-6 and the resulting inhibition of their activity were studied by means of extensive molecular-dynamics simulations. The effect of LMWH on IFNγ signalling inside stimulated WISH cells was investigated by measuring its antiproliferative activity and the translocation of phosphorylated STAT1 in the nucleus. We found that LMWH binds with high affinity to IFNγ and is able to fully inhibit the interaction with its cellular receptor. It also influences the biological activity of IL-6 by binding to either IL-6 or IL-6/IL-6Rα, thus preventing the formation of the IL-6/IL-6Rα/gp130 signalling complex. These findings shed light on the molecular mechanism of the anti-inflammatory action of LMWH and underpin its ability to influence favourably conditions characterised by overexpression of these two cytokines. Such conditions are not only associated with autoimmune diseases, but also with inflammatory processes, in particular with COVID-19. Our results put forward heparin as a promising means for the prevention and suppression of severe CRS and encourage further investigations on its applicability as an anti-inflammatory agent.